AMBARELLA INC — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that AMBARELLA INC filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Jan 31, 2018 | $295.40M | Mar 30, 2018 |
| FY2018 | Jan 31, 2017 | $310.30M | Mar 30, 2018 |
| FY2018 | Jan 31, 2016 | $316.37M | Mar 30, 2018 |
| FY2017 | Jan 31, 2015 | $218.28M | Mar 30, 2017 |
| FY2016 | Jan 31, 2014 | $157.61M | Mar 25, 2016 |
| FY2015 | Jan 31, 2013 | $121.07M | Mar 30, 2015 |
| FY2013 | Jan 31, 2012 | $97.26M | Apr 4, 2014 |
| FY2012 | Jan 31, 2011 | $94.74M | Apr 4, 2013 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 31, 2026 | $390.70M | Mar 23, 2026 |
| FY2026 | Jan 31, 2025 | $284.87M | Mar 23, 2026 |
| FY2026 | Jan 31, 2024 | $226.47M | Mar 23, 2026 |
| FY2025 | Jan 31, 2023 | $337.61M | Mar 28, 2025 |
| FY2024 | Jan 31, 2022 | $331.86M | Mar 29, 2024 |
| FY2023 | Jan 31, 2021 | $222.99M | Mar 31, 2023 |
| FY2022 | Jan 31, 2020 | $228.73M | Apr 1, 2022 |
| FY2021 | Jan 31, 2019 | $227.77M | Mar 31, 2021 |
| FY2020 | Jan 31, 2018 | $295.40M | Mar 27, 2020 |
| FY2019 | Jan 31, 2017 | $310.30M | Mar 29, 2019 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 31, 2026 | $231.27M | Mar 23, 2026 |
| FY2026 | Jan 31, 2025 | $172.33M | Mar 23, 2026 |
| FY2026 | Jan 31, 2024 | $136.82M | Mar 23, 2026 |
| FY2025 | Jan 31, 2023 | $208.93M | Mar 28, 2025 |
| FY2024 | Jan 31, 2022 | $208.13M | Mar 29, 2024 |
| FY2023 | Jan 31, 2021 | $135.57M | Mar 31, 2023 |
| FY2022 | Jan 31, 2020 | $132.71M | Apr 1, 2022 |
| FY2021 | Jan 31, 2019 | $138.14M | Mar 31, 2021 |
| FY2020 | Jan 31, 2018 | $187.73M | Mar 27, 2020 |
| FY2019 | Jan 31, 2017 | $205.01M | Mar 29, 2019 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 31, 2026 | ($75.87M) | Mar 23, 2026 |
| FY2026 | Jan 31, 2025 | ($117.13M) | Mar 23, 2026 |
| FY2026 | Jan 31, 2024 | ($169.42M) | Mar 23, 2026 |
| FY2025 | Jan 31, 2023 | ($65.39M) | Mar 28, 2025 |
| FY2024 | Jan 31, 2022 | ($26.41M) | Mar 29, 2024 |
| FY2023 | Jan 31, 2021 | ($59.79M) | Mar 31, 2023 |
| FY2022 | Jan 31, 2020 | ($44.79M) | Apr 1, 2022 |
| FY2021 | Jan 31, 2019 | ($30.45M) | Mar 31, 2021 |
| FY2020 | Jan 31, 2018 | $18.85M | Mar 27, 2020 |
| FY2019 | Jan 31, 2017 | $57.81M | Mar 29, 2019 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 31, 2026 | ($82.53M) | Mar 23, 2026 |
| FY2026 | Jan 31, 2025 | ($126.60M) | Mar 23, 2026 |
| FY2026 | Jan 31, 2024 | ($154.56M) | Mar 23, 2026 |
| FY2025 | Jan 31, 2023 | ($74.26M) | Mar 28, 2025 |
| FY2024 | Jan 31, 2022 | ($29.64M) | Mar 29, 2024 |
| FY2023 | Jan 31, 2021 | ($61.17M) | Mar 31, 2023 |
| FY2022 | Jan 31, 2020 | ($49.65M) | Apr 1, 2022 |
| FY2021 | Jan 31, 2019 | ($40.42M) | Mar 31, 2021 |
| FY2020 | Jan 31, 2018 | $24.43M | Mar 27, 2020 |
| FY2019 | Jan 31, 2017 | $60.36M | Mar 29, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 31, 2026 | $238.52M | Mar 23, 2026 |
| FY2026 | Jan 31, 2025 | $226.11M | Mar 23, 2026 |
| FY2026 | Jan 31, 2024 | $215.05M | Mar 23, 2026 |
| FY2025 | Jan 31, 2023 | $204.95M | Mar 28, 2025 |
| FY2024 | Jan 31, 2022 | $167.34M | Mar 29, 2024 |
| FY2023 | Jan 31, 2021 | $140.76M | Mar 31, 2023 |
| FY2022 | Jan 31, 2020 | $129.72M | Apr 1, 2022 |
| FY2021 | Jan 31, 2019 | $128.08M | Mar 31, 2021 |
| FY2020 | Jan 31, 2018 | $115.51M | Mar 27, 2020 |
| FY2019 | Jan 31, 2017 | $101.21M | Mar 29, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 31, 2026 | $75.27M | Mar 23, 2026 |
| FY2026 | Jan 31, 2025 | $72.82M | Mar 23, 2026 |
| FY2026 | Jan 31, 2024 | $76.33M | Mar 23, 2026 |
| FY2025 | Jan 31, 2023 | $78.24M | Mar 28, 2025 |
| FY2024 | Jan 31, 2022 | $70.44M | Mar 29, 2024 |
| FY2023 | Jan 31, 2021 | $55.98M | Mar 31, 2023 |
| FY2022 | Jan 31, 2020 | $52.63M | Apr 1, 2022 |
| FY2021 | Jan 31, 2019 | $50.48M | Mar 31, 2021 |
| FY2020 | Jan 31, 2018 | $47.79M | Mar 27, 2020 |
| FY2019 | Jan 31, 2017 | $43.45M | Mar 29, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 31, 2026 | $73.52M | Mar 23, 2026 |
| FY2026 | Jan 31, 2025 | $33.84M | Mar 23, 2026 |
| FY2026 | Jan 31, 2024 | $19.02M | Mar 23, 2026 |
| FY2025 | Jan 31, 2023 | $44.09M | Mar 28, 2025 |
| FY2024 | Jan 31, 2022 | $38.80M | Mar 29, 2024 |
| FY2023 | Jan 31, 2021 | $30.80M | Mar 31, 2023 |
| FY2022 | Jan 31, 2020 | $39.41M | Apr 1, 2022 |
| FY2021 | Jan 31, 2019 | $24.47M | Mar 31, 2021 |
| FY2020 | Jan 31, 2018 | $85.40M | Mar 27, 2020 |
| FY2019 | Jan 31, 2017 | $113.32M | Mar 29, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Jan 31, 2021 | $1.95M | Mar 31, 2021 |
| FY2021 | Jan 31, 2020 | $1.82M | Mar 31, 2021 |
| FY2021 | Jan 31, 2019 | $2.94M | Mar 31, 2021 |
| FY2020 | Jan 31, 2018 | $3.69M | Mar 27, 2020 |
| FY2019 | Jan 31, 2017 | $2.70M | Mar 29, 2019 |
| FY2018 | Jan 31, 2016 | $2.09M | Mar 30, 2018 |
| FY2017 | Jan 31, 2015 | $1.36M | Mar 30, 2017 |
| FY2016 | Jan 31, 2014 | $1.70M | Mar 25, 2016 |
| FY2015 | Jan 31, 2013 | $1.53M | Mar 30, 2015 |
| FY2013 | Jan 31, 2012 | $682.0K | Apr 4, 2014 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 31, 2026 | $798.60M | Mar 23, 2026 |
| FY2026 | Jan 31, 2025 | $688.97M | Mar 23, 2026 |
| FY2025 | Jan 31, 2024 | $657.66M | Mar 28, 2025 |
| FY2024 | Jan 31, 2023 | $710.20M | Mar 29, 2024 |
| FY2023 | Jan 31, 2022 | $657.55M | Mar 31, 2023 |
| FY2022 | Jan 31, 2021 | $573.28M | Apr 1, 2022 |
| FY2021 | Jan 31, 2020 | $527.28M | Mar 31, 2021 |
| FY2020 | Jan 31, 2019 | $466.85M | Mar 27, 2020 |
| FY2019 | Jan 31, 2018 | $546.65M | Mar 29, 2019 |
| FY2018 | Jan 31, 2017 | $512.27M | Mar 30, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 31, 2026 | $203.81M | Mar 23, 2026 |
| FY2026 | Jan 31, 2025 | $127.56M | Mar 23, 2026 |
| FY2025 | Jan 31, 2024 | $97.78M | Mar 28, 2025 |
| FY2024 | Jan 31, 2023 | $104.11M | Mar 29, 2024 |
| FY2023 | Jan 31, 2022 | $110.37M | Mar 31, 2023 |
| FY2022 | Jan 31, 2021 | $98.30M | Apr 1, 2022 |
| FY2021 | Jan 31, 2020 | $79.20M | Mar 31, 2021 |
| FY2020 | Jan 31, 2019 | $47.36M | Mar 27, 2020 |
| FY2019 | Jan 31, 2018 | $64.46M | Mar 29, 2019 |
| FY2018 | Jan 31, 2017 | $57.64M | Mar 30, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 31, 2026 | $594.79M | Mar 23, 2026 |
| FY2026 | Jan 31, 2025 | $561.41M | Mar 23, 2026 |
| FY2026 | Jan 31, 2024 | $559.87M | Mar 23, 2026 |
| FY2026 | Jan 31, 2023 | $606.09M | Mar 23, 2026 |
| FY2025 | Jan 31, 2022 | $547.18M | Mar 28, 2025 |
| FY2024 | Jan 31, 2021 | $474.98M | Mar 29, 2024 |
| FY2023 | Jan 31, 2020 | $448.07M | Mar 31, 2023 |
| FY2022 | Jan 31, 2019 | $419.49M | Apr 1, 2022 |
| FY2021 | Jan 31, 2018 | $482.19M | Mar 31, 2021 |
| FY2020 | Jan 31, 2017 | $454.63M | Mar 27, 2020 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 31, 2026 | $303.63M | Mar 23, 2026 |
| FY2026 | Jan 31, 2025 | $303.63M | Mar 23, 2026 |
| FY2025 | Jan 31, 2024 | $303.63M | Mar 28, 2025 |
| FY2024 | Jan 31, 2023 | $303.63M | Mar 29, 2024 |
| FY2023 | Jan 31, 2022 | $303.63M | Mar 31, 2023 |
| FY2022 | Jan 31, 2021 | $26.60M | Apr 1, 2022 |
| FY2021 | Jan 31, 2020 | $26.60M | Mar 31, 2021 |
| FY2020 | Jan 31, 2019 | $26.60M | Mar 27, 2020 |
| FY2019 | Jan 31, 2018 | $26.60M | Mar 29, 2019 |
| FY2018 | Jan 31, 2017 | $26.60M | Mar 30, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 31, 2026 | ($327.92M) | Mar 23, 2026 |
| FY2026 | Jan 31, 2025 | ($252.06M) | Mar 23, 2026 |
| FY2025 | Jan 31, 2024 | ($134.93M) | Mar 28, 2025 |
| FY2024 | Jan 31, 2023 | $34.49M | Mar 29, 2024 |
| FY2023 | Jan 31, 2022 | $99.87M | Mar 31, 2023 |
| FY2022 | Jan 31, 2021 | $126.28M | Apr 1, 2022 |
| FY2021 | Jan 31, 2020 | $186.07M | Mar 31, 2021 |
| FY2020 | Jan 31, 2019 | $230.86M | Mar 27, 2020 |
| FY2019 | Jan 31, 2018 | $261.27M | Mar 29, 2019 |
| FY2018 | Jan 31, 2017 | $242.41M | Mar 30, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 31, 2026 | $191.02M | Mar 23, 2026 |
| FY2026 | Jan 31, 2025 | $144.62M | Mar 23, 2026 |
| FY2026 | Jan 31, 2024 | $144.91M | Mar 23, 2026 |
| FY2025 | Jan 31, 2023 | $113.54M | Mar 28, 2025 |
| FY2024 | Jan 31, 2022 | $171.04M | Mar 29, 2024 |
| FY2023 | Jan 31, 2021 | $241.27M | Mar 31, 2023 |
| FY2022 | Jan 31, 2020 | $231.40M | Apr 1, 2022 |
| FY2021 | Jan 31, 2019 | $194.05M | Mar 31, 2021 |
| FY2020 | Jan 31, 2018 | $346.67M | Mar 27, 2020 |
| FY2019 | Jan 31, 2017 | $322.87M | Mar 29, 2019 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 31, 2026 | (1) | Mar 23, 2026 |
| FY2026 | Jan 31, 2025 | (2) | Mar 23, 2026 |
| FY2026 | Jan 31, 2024 | (4) | Mar 23, 2026 |
| FY2025 | Jan 31, 2023 | (1) | Mar 28, 2025 |
| FY2024 | Jan 31, 2022 | 0 | Mar 29, 2024 |
| FY2023 | Jan 31, 2021 | (1) | Mar 31, 2023 |
| FY2022 | Jan 31, 2020 | (1) | Apr 1, 2022 |
| FY2021 | Jan 31, 2019 | 0 | Mar 31, 2021 |
| FY2020 | Jan 31, 2018 | 0 | Mar 27, 2020 |
| FY2019 | Jan 31, 2017 | 1 | Mar 29, 2019 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 31, 2026 | (1) | Mar 23, 2026 |
| FY2026 | Jan 31, 2025 | (2) | Mar 23, 2026 |
| FY2026 | Jan 31, 2024 | (4) | Mar 23, 2026 |
| FY2025 | Jan 31, 2023 | (1) | Mar 28, 2025 |
| FY2024 | Jan 31, 2022 | 0 | Mar 29, 2024 |
| FY2023 | Jan 31, 2021 | (1) | Mar 31, 2023 |
| FY2022 | Jan 31, 2020 | (1) | Apr 1, 2022 |
| FY2021 | Jan 31, 2019 | 0 | Mar 31, 2021 |
| FY2020 | Jan 31, 2018 | 0 | Mar 27, 2020 |
| FY2019 | Jan 31, 2017 | 1 | Mar 29, 2019 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 31, 2026 | 43.31M | Mar 23, 2026 |
| FY2026 | Jan 31, 2025 | 41.96M | Mar 23, 2026 |
| FY2025 | Jan 31, 2024 | 40.52M | Mar 28, 2025 |
| FY2024 | Jan 31, 2023 | 39.04M | Mar 29, 2024 |
| FY2023 | Jan 31, 2022 | 37.30M | Mar 31, 2023 |
| FY2022 | Jan 31, 2021 | 35.55M | Apr 1, 2022 |
| FY2021 | Jan 31, 2020 | 33.81M | Mar 31, 2021 |
| FY2020 | Jan 31, 2019 | 32.30M | Mar 27, 2020 |
| FY2019 | Jan 31, 2018 | 33.49M | Mar 29, 2019 |
| FY2018 | Jan 31, 2017 | 33.37M | Mar 30, 2018 |